STOCK TITAN

Ayala Pharmaceuticals, Inc. - AYLA STOCK NEWS

Welcome to our dedicated page for Ayala Pharmaceuticals news (Ticker: AYLA), a resource for investors and traders seeking the latest updates and insights on Ayala Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ayala Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ayala Pharmaceuticals's position in the market.

Rhea-AI Summary

Ayala Pharmaceuticals reported promising data at ESMO 2021 for AL101 in treating recurrent/metastatic adenoid cystic carcinoma, showing a 70% disease control rate. The company highlighted its ongoing clinical trials, particularly the RINGSIDE trial for desmoid tumors and a combination study for multiple myeloma with Novartis. Financially, Ayala had $40.8 million in cash as of September 30, 2021, but reported a net loss of $9.8 million for Q3 2021, compared to $7.4 million in Q3 2020. The company anticipates multiple milestones in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) will participate in a fireside chat at the Jefferies London Healthcare Conference on November 17, 2021, at 5:00 PM GMT (12:00 PM ET). The event will be accessible via a live webcast on Ayala's website, with an archived replay available for 90 days post-event. Ayala focuses on developing small molecule therapeutics for rare cancers, with two key candidates, AL101 and AL102, in clinical trials. AL101 has received Fast Track and Orphan Drug Designation from the FDA, targeting tumors with Notch activating mutations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) announced the publication of two case studies in Current Oncology demonstrating the effectiveness of its gamma secretase inhibitor, AL101, for treating desmoid tumors. Both patients showed significant tumor reductions: 41% and 60% after 55 and 82 weeks of treatment, respectively. The company is advancing to a pivotal Phase 2/3 trial, RINGSIDE, to evaluate AL102's efficacy and safety in desmoid tumors. This trial aims to fill a significant treatment gap as there are currently no FDA-approved therapies for unresectable or progressive cases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) presented preliminary data from its Phase 2 ACCURACY trial for AL101 at the ESMO Virtual Congress 2021. The 6mg monotherapy showed a 70% disease control rate in patients with recurrent/metastatic adenoid cystic carcinoma (ACC) harboring Notch mutations. The treatment was well tolerated, with manageable side effects. Preliminary results indicate promising efficacy, with 9% partial responses and 61% stable disease among evaluable patients. Future updates on the trial are anticipated in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) announced participation in two virtual investor conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investor Conference will feature an on-demand corporate presentation available from September 13. Additionally, management will participate in meetings at Citi’s 16th Annual Biopharma Virtual Conference on September 9. Ayala focuses on developing small molecule therapeutics for rare and aggressive cancers, with two product candidates, AL101 and AL102, in advanced clinical trials targeting various cancers. More details can be found on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) announced ePoster presentations at the ESMO Virtual Congress 2021, scheduled for September 16-21, 2021. The presentations will feature preliminary data from the Phase 2 ACCURACY trial of AL101, a gamma secretase inhibitor aimed at treating recurrent/metastatic adenoid cystic carcinoma with Notch-activating mutations. Additionally, preclinical results for AL101 in combination therapies will be presented. AL101 has received Fast Track and Orphan Drug Designations from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
Rhea-AI Summary

Ayala Pharmaceuticals (Nasdaq: AYLA) has enrolled the first patient in the Phase 2/3 pivotal trial of AL102 for desmoid tumors, marking a significant milestone. The company reported a net loss of $10.8 million for Q2 2021, with cash and equivalents at $44.4 million. R&D expenses rose to $8.1 million, reflecting advancements in clinical programs. Collaboration revenue decreased to $0.8 million. Upcoming milestones include data from the ACCURACY trial presented at ESMO 2021 and further progress in trials for multiple myeloma and triple-negative breast cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) will have its CEO, Roni Mamluk, present at the Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 9:00 am ET. Ayala is focused on developing small molecule therapeutics for rare and aggressive cancers. Their lead candidates, AL101 and AL102, are in various clinical trials targeting cancers like Adenoid Cystic Carcinoma and Triple Negative Breast Cancer. Both products have received FDA designations to expedite their development. The live webcast can be accessed on Ayala's website, with a replay available for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Ayala Pharmaceuticals (NASDAQ: AYLA) announced CEO Roni Mamluk will participate in two virtual investor conferences. The events include the Jefferies Virtual Healthcare Conference on June 2, 2021, at 3:00 pm ET for a fireside chat and the Raymond James Human Health Innovation Conference on June 21, 2021, at 10:00 am ET for a corporate presentation. Live webcasts can be accessed on Ayala's website, with replays available for 90 days. Ayala focuses on developing therapies for rare cancers, with candidates AL101 and AL102 targeting specific tumor types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) announced the first patient dosing in its Phase 1 AL102 combination trial with Novartis for treating multiple myeloma. The company is on track to initiate a Phase 2/3 pivotal trial for AL102 in desmoid tumors. Ayala reported a cash position of $56 million as of March 31, 2021, after completing a $25 million strategic financing in February. In Q1 2021, the company recorded a net loss of $9.6 million, with R&D expenses increasing to $6.9 million. The cash runway is expected to last into 2023, supporting upcoming milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the market cap of Ayala Pharmaceuticals (AYLA)?

The market cap of Ayala Pharmaceuticals (AYLA) is approximately 7.9M.
Ayala Pharmaceuticals, Inc.

Nasdaq:AYLA

AYLA Rankings

AYLA Stock Data

7.91M
10.41M
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link